BiotechFQ
@biotechfq.bsky.social did:plc:wvb24cwtbzkq4tnyhwm322sw
#Biotech #GeneEditing #AI #IPSC #Neuroscience #Epigenetics #TPD
Bluesky’a katılma tarihi:
- Takipçi
- 8
- Takip edilen
- 13
- Post
- 8
- Sıralamaya girdiği gün
- 0
Özet
BiotechFQ (@biotechfq.bsky.social), 17 Kasım 2024 tarihinde katılan bir Bluesky kullanıcısı. 8 takipçisi var, 13 hesabı takip ediyor ve 8 post paylaştı.
Sıralama geçmişi
Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.
Bu hesap henüz günlük sıralamaya girmedi.
Son beğendiği postlar
Bluesky ağındaki herkese açık beğeniler.
$ARVN Phase 3 VERITAC-2 trial showed that Vepdegestrant monotherapy significantly improves progression-free survival in ER+/HER2 breast cancer patients with ESR1 mutations, but not in the overall patient population. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/2s...
Postu gösterRoche signs biggest-ever obesity drug deal with Danish Zealand Pharma; $5.3bn licensing agreement for next-generation treatment. www.ft.com/content/80c5...
Postu gösterZealand Pharma ( $ZEAL.CO) partners with Roche on its amylin analog in a deal worth up to $5.3B, plus 50% upside on profits, with $1.65Bn upfront! 👏 endpts.com/zealand-part...
Postu göster$TSVT announced a merger agreement with $BMY to be acquired for $5.00 per share in an all-cash deal valued at $286 million, representing an 88% premium to its March 7, 2025 closing price. See More Pre-market Movers 👇 www.biopharmcatalyst.com/news/2025/2s... $ARVN $CUTR $SNOA $TNON $BVS $MYO $HCSC
Postu göster$BTAI announced that it has achieved 33% enrollment in its 200-patient SERENITY At-Home trial, a pivotal Phase 3 study assessing the safety of BXCL501. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/bi...
Postu göster
Blokladığı hesaplar
Bluesky’da bloklar herkese açık kayıtlardır.
Bu hesap kimseyi bloklamıyor.